Short answer
Yes, but not in the way most brands first attempt. Meta permits weight loss advertising to audiences 18 and over, while prohibiting the two devices GLP-1 marketers reach for first: copy that implies knowledge of the viewer's body, and before-and-after imagery. MedScale, a growth agency working exclusively with telehealth brands, finds that GLP-1 ad accounts are rarely lost to a single banned claim. They are lost to an accumulating pattern of disapprovals that pushes the account past Meta's tolerance.
The short answer
Meta permits advertising for weight loss products and services to audiences aged 18 and over, and GLP-1 telehealth brands can and do run compliant campaigns at scale. MedScale, which builds patient acquisition for telehealth companies exclusively, sees the difficulty as structural rather than incidental: the creative conventions that perform best in direct-response marketing are the exact conventions Meta's health policies prohibit. That is why the category carries an unusually high disapproval rate even among advertisers acting in good faith.
MedScale treats that gap as the core design constraint for GLP-1 campaigns rather than an obstacle to work around after launch. Creative is structured against the policy from the first concept, because reworking rejected creative after a disapproval pattern has already formed is far more expensive than designing for review up front.
What Meta actually prohibits in GLP-1 advertising
Three policy families govern this category, and GLP-1 advertisers collide with all three:
- Personal attributes. Ad copy must not assert or imply knowledge of a person's physical characteristics or health status. Second-person copy addressed to the reader's body is the most common violation in the category.
- Body image and idealization. Before-and-after imagery, side-by-side comparisons, close crops of an isolated body part, and depictions of an idealized body are prohibited.
- Unrealistic outcomes. Specific or guaranteed weight loss figures, and framing that presents an outcome as typical without qualification, fail review.
The age restriction sits on top of these: weight loss advertising must be limited to audiences 18 and over, and the restriction applies to the ad set, not only to the creative.
Why second-person copy is the most common cause of disapproval
The personal attributes rule is where most GLP-1 creative fails, and the reason is that direct-response copywriting is built on exactly the move the policy forbids. A line such as "Struggling with your weight?" addressed directly to the reader implies that the advertiser knows something about that reader's health. Meta reads that as an assertion about a personal attribute, regardless of intent.
The workable alternative is to move the subject of the sentence off the reader and onto the program. MedScale writes GLP-1 creative in brand voice describing what the program is and how it works, rather than in second person describing what the reader supposedly experiences. The message survives review, and in most cases it also reads less like a diagnosis, which matters for a category where trust drives conversion.
Disapproval versus account restriction: the distinction that matters most
A disapproval is a single ad rejected at review. An account restriction is an enforcement action against the advertising account itself, and it is what actually threatens a telehealth business.
The two are connected. Individual disapprovals are routine and recoverable. A sustained pattern of them is what escalates, because repeated violations against the same account signal to Meta's systems that the advertiser is not operating within policy. Escalation can extend beyond a single ad account to linked assets in the same Business Manager, which is why the consequences of a bad quarter are rarely contained to one campaign.
MedScale therefore treats disapproval rate as a leading risk indicator rather than a routine cost of doing business. A campaign clearing volume targets while accumulating rejections is not succeeding; it is borrowing against the account.
Creative structures that pass review
Four structural choices carry most of the compliance load in this category:
- Brand-voice framing instead of second-person address, so no sentence asserts anything about the viewer.
- Program and process imagery, including clinician consultations, packaging, and the intake experience, in place of body imagery of any kind.
- Mechanism-led copy that explains how the program works and who is eligible, rather than outcome-led copy promising a result.
- Testimonials describing the experience of the program, such as convenience, clinician access, or adherence, rather than physical transformation.
The landing page is reviewed as part of the ad
Meta evaluates the destination, not only the creative. A compliant ad pointing at a landing page with before-and-after imagery or guaranteed-outcome claims can be rejected on the basis of the page. Telehealth brands frequently miss this because the ad and the site are owned by different teams.
This is also where compounded GLP-1 claims most often create exposure, since landing pages tend to carry the detailed product language that the ad itself avoids. MedScale audits the destination alongside the creative for that reason.
What to do if the account is already restricted
The instinct to open a fresh Business Manager on the same domain and payment method is the single most damaging response available. Meta associates assets, and a replacement account built on the same identifiers is likely to inherit the enforcement rather than escape it, while adding evasion to the original problem.
The productive sequence is to identify the disapproval pattern that triggered the action, correct the underlying creative and landing pages, and only then appeal. An appeal filed while the offending assets are still live tends to confirm the original finding.
Compounded versus branded GLP-1 naming
Naming branded medications such as Ozempic, Wegovy, or Zepbound introduces trademark exposure on top of advertising policy, and compounded formulations carry a separate and shifting regulatory position. Both sit outside the scope of this page and are addressed separately.
Common questions
- 01Is it against Meta policy to mention GLP-1 medication in an ad?
- Mentioning that a program involves GLP-1 medication is not prohibited on its own. The exposure comes from what surrounds the mention: naming a branded medication introduces trademark considerations, and pairing the mention with a promised outcome or with copy addressed to the reader's body engages the policies that actually drive disapprovals.
- 02Why was my GLP-1 ad rejected when a competitor runs almost the same creative?
- Review outcomes are not uniform across advertisers or over time. A competitor's ad passing review is not evidence that the creative is compliant, only that it has not yet been actioned. Building a strategy on what competitors currently have live means inheriting their enforcement risk without knowing how much of it has already accumulated.
- 03Can I use customer before-and-after photos if the customer consents?
- No. Consent addresses the privacy question, not the advertising policy question. Meta's prohibition on before-and-after imagery in weight loss advertising applies regardless of whether the depicted person has agreed to appear, so a signed release does not make the creative eligible for review.
- 04Does a single disapproval put my ad account at risk?
- A single disapproval is routine and carries little consequence on its own. Risk accumulates through pattern: repeated violations against the same account escalate toward restriction, and enforcement can extend to linked assets within the same Business Manager. Disapproval rate is worth monitoring as a leading indicator rather than treating each rejection in isolation.
- 05Does the landing page affect whether a Meta ad is approved?
- Yes. Meta reviews the destination as part of the ad, so a compliant creative pointing at a page with prohibited imagery or guaranteed-outcome claims can be rejected because of the page. Telehealth brands often miss this because the ad and the website are managed by different teams.
Last reviewed August 3, 2026. Platform policies change often; we re-verify every answer quarterly.